| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Eberhardt W | |
| Pfeilschifter J | |||
| P2860 | cites work | Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis | Q73396248 |
| Progression and potential regression of glomerulosclerosis | Q73419751 | ||
| Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis | Q73951463 | ||
| Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells | Q74387871 | ||
| Nitric oxide increases matrix metalloproteinase-1 production in human uterine cervical fibroblast cells | Q74562362 | ||
| Nitric oxide and glomerulonephritis | Q77647521 | ||
| Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression | Q77997609 | ||
| Nitric oxide and the regulation of gene expression | Q34134480 | ||
| Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells | Q34150690 | ||
| Regulation of gene expression by nitric oxide | Q34340303 | ||
| NO as a signaling molecule: effects on kinases. | Q34342620 | ||
| Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation | Q34367567 | ||
| Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets | Q34430700 | ||
| NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts | Q34453246 | ||
| Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. | Q34542211 | ||
| Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells | Q34573717 | ||
| The progression of renal disease | Q34661353 | ||
| Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator | Q35043783 | ||
| The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism | Q35096108 | ||
| Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. | Q35107873 | ||
| Nitric oxide and mechanisms of redox signaling | Q35182358 | ||
| Reactive oxygen species and matrix remodeling in diabetic kidney | Q35182366 | ||
| Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases | Q35187217 | ||
| Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage | Q35604343 | ||
| Progression and regression in renal vascular and glomerular fibrosis. | Q35758342 | ||
| Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? | Q35840821 | ||
| Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture | Q35993294 | ||
| A heretical view on the role of NO and cGMP in vascular proliferative diseases | Q36032424 | ||
| The pathobiology of the mesangium | Q36058073 | ||
| Nitric oxide in wound-healing. | Q36207435 | ||
| Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. | Q36279580 | ||
| Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates | Q36305029 | ||
| Atherosclerosis and proteinase activation | Q36352662 | ||
| The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orall | Q36362801 | ||
| Redox signaling in hypertension | Q36502131 | ||
| Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action | Q36621198 | ||
| Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts | Q37272222 | ||
| Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin | Q37383608 | ||
| Nitric oxide. A novel signal transduction mechanism for transcellular communication | Q37602538 | ||
| Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability | Q38287524 | ||
| Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. | Q38350318 | ||
| TGF-beta signal transduction | Q22003891 | ||
| The L-arginine-nitric oxide pathway | Q24304874 | ||
| Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism | Q24674746 | ||
| Matrix metalloproteinases | Q28140451 | ||
| AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes | Q28568784 | ||
| Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model | Q28578669 | ||
| New functions for the matrix metalloproteinases in cancer progression | Q29547738 | ||
| Structure and function of matrix metalloproteinases and TIMPs | Q30014818 | ||
| Angiotensin II and nitric oxide: a question of balance | Q30304121 | ||
| Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice | Q30448786 | ||
| S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death | Q30843579 | ||
| Regression of renal vascular fibrosis by endothelin receptor antagonism | Q32071631 | ||
| Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface | Q33200943 | ||
| Inhaled nitric oxide inhibits the release of matrix metalloproteinase-2, but not platelet activation, during extracorporeal membrane oxygenation in adult rabbits | Q33347331 | ||
| Mechanisms for pro matrix metalloproteinase activation. | Q33586441 | ||
| Nitric oxide in the pathogenesis of vascular disease | Q33843539 | ||
| Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta | Q33902166 | ||
| Molecular basis of renal fibrosis | Q34125332 | ||
| Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines | Q38360427 | ||
| Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition | Q38488930 | ||
| Exogenous nitric oxide causes overexpression of TGF-beta1 and overproduction of extracellular matrix in human coronary smooth muscle cells | Q39394032 | ||
| Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy | Q40444286 | ||
| Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase | Q40467971 | ||
| Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells | Q40757990 | ||
| Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies | Q40786541 | ||
| Atherosclerotic renovascular disease and progressive renal failure | Q40890763 | ||
| Signalling by cGMP-dependent protein kinases | Q41062596 | ||
| Nitric oxide modulates the c-Jun N-terminal kinase/stress-activated protein kinase activity through activating c-Jun N-terminal kinase kinase | Q41081909 | ||
| Nitric oxide-stimulated guanine nucleotide exchange on p21ras | Q41357997 | ||
| Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of ma | Q42492012 | ||
| Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix | Q42799009 | ||
| Modulation of angiotensin-converting enzyme by nitric oxide | Q43183129 | ||
| Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro | Q43661018 | ||
| Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition | Q43705520 | ||
| Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells | Q43850920 | ||
| Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. | Q43862772 | ||
| L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis | Q44358741 | ||
| Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases | Q44411510 | ||
| Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle | Q44572946 | ||
| Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-kappaB and activator protein-1 activity | Q44734355 | ||
| Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells | Q44854922 | ||
| Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect | Q45116492 | ||
| eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity | Q46177756 | ||
| Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway | Q46720418 | ||
| The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants | Q46868467 | ||
| Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated prot | Q47816419 | ||
| Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion | Q49157459 | ||
| Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. | Q53629670 | ||
| l-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis | Q56987375 | ||
| Nitric oxide regulates matrix metalloprotease-13 expression and activity in endothelium | Q57082642 | ||
| Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication | Q57791545 | ||
| Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells | Q58816342 | ||
| Distribution of type I collagen in human kidney diseases in comparison with type III collagen | Q68618657 | ||
| Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells | Q70946247 | ||
| Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus | Q71012849 | ||
| Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics | Q71058105 | ||
| Expression of inducible-NOS in human glomerulonephritis: the possible source is infiltrating monocytes/macrophages | Q71612610 | ||
| Restenosis is associated with decreased coronary artery nitric oxide synthase | Q71617776 | ||
| L-arginine enhances injury in the isolated rabbit lung during hyperoxia | Q71700369 | ||
| Manipulation of the L-arginine-nitric oxide pathway in experimental colitis | Q71725168 | ||
| Nitric oxide (NO) in renal physiology and pathophysiology | Q71779057 | ||
| Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells | Q73322114 | ||
| P433 | issue | 106 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microvasculature remodeling | Q6840464 |
| P304 | page(s) | S9-S16 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Kidney International. Supplement | Q26842696 |
| P1476 | title | Nitric oxide and vascular remodeling: spotlight on the kidney |
| Q37721284 | A conceptual framework for the molecular pathogenesis of progressive kidney disease. |
| Q35817958 | Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension |
| Q37197098 | Inflammation in renal atherosclerotic disease |
| Q59799492 | Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
| Q30300218 | Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage |
| Q46453523 | Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: Insights in the underlying mechanisms. |
| Q38965294 | The vertebrate homologue of sulfide-quinone reductase in mammalian mitochondria |
Search more.